Silence Therapeutics PLC Directorate Change (7347F)
May 29 2013 - 2:01AM
UK Regulatory
TIDMSLN
RNS Number : 7347F
Silence Therapeutics PLC
29 May 2013
Appointment of chief executive and director of corporate
development
29(th) May 2013
Silence Therapeutics plc (AIM: SLN) announces today the
appointment of Ali Mortazavi as chief executive and of Annie Cheng
as director of corporate development.
Ali Mortazavi joined Silence in August 2012 as director of
corporate strategy and since that time has increasingly taken on
the mantle of the CEO role. This included overseeing two
fundraisings last year to raise GBP11m for the company and
spearheading the GBP19m placing completed in April 2013. Ali has
over 17 years of experience in financial services. He started his
career as a Technology Analyst at Duncan Lawrie then Credit
Lyonnais Securities. In 2001, he co-founded Evolution Securities
and ran the principal trading and market making arm, leaving in
2008. He has extensive experience in small companies and has had
significant stakes in UK listed technology / biotech ventures.
Annie Cheng (Annie Jia Huey Cheng), age 37, joins the company
after working as a strategy consultant for the Company since
October 2012. She has 14 years of experience in the healthcare
industry, in equity research and consulting with JP Morgan and
boutique investment banks in New York and London.
She has been a director of Visible Value LLP, a biotech
consultancy, since December 2011 and of Valor Visible Ltd, its
associated business, since October 2012.
There are no other matters to disclose regarding her appointment
under Rule 17 or Schedule 2 paragraph (g) of the AIM Rules for
Companies.
Chairman Jerry Randall said: 'Ali brings a wealth of experience
in the capital markets as well as small cap companies, and has been
instrumental in the development of Silence since he joined. Annie's
combination of investor and commercial experience is very
valuable.'
Silence Therapeutics
Ali Mortazavi, chief executive/Timothy Freeborn, finance
director +44 (0)333 988 0140
a.mortazavi@silence-therapeutics.com
t.freeborn@silence-therapeutics.com
N+1 Singer
Shaun Dobson/Jenny Wyllie
+44 20 7496 3000
shaun.dobson@n1singer.com
jenny.wyllie@n1singer.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOAPGUBPAUPWGQR
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From Jul 2023 to Jul 2024